{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:58:04Z","timestamp":1790578684314,"version":"4.1.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-026-00897-y","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:10:29Z","timestamp":1790575829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FIIX-based vitamin K antagonist monitoring: the promise of improved anticoagulation stability and clinical outcomes in mechanical heart valve patients"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-919X","authenticated-orcid":false,"given":"Stephanie","family":"Carlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Belley-Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"897_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-026-00886-1","author":"X Luo","year":"2026","unstructured":"Luo X, Yang X, Sun T, Yan X. Perioperative management in a patient with congenital factor VII deficiency following mechanical valve replacement: a case report. Thromb J. 2026. https:\/\/doi.org\/10.1186\/s12959-026-00886-1.","journal-title":"Thromb J"},{"key":"897_CR2","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/S2352-3026(15)00073-3","volume":"2","author":"PT Onundarson","year":"2015","unstructured":"Onundarson PT, Francis CW, Indridason OS, et al. Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single-centre, double-blind, randomised, non-inferiority trial. Lancet Haematol. 2015;2:e231\u201340.","journal-title":"Lancet Haematol"},{"key":"897_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12959-021-00327-1","volume":"19","author":"PT Onundarson","year":"2021","unstructured":"Onundarson PT, Palsson R, Witt DM, Gudmundsdottir BR. Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. Thromb J. 2021;19:72.","journal-title":"Thromb J"},{"key":"897_CR4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.5858\/2009-0474-OA.1","volume":"135","author":"G Gulati","year":"2011","unstructured":"Gulati G, Hevelow M, George M, Behling E, Siegel J. International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy. Arch Pathol Lab Med. 2011;135:490\u20134.","journal-title":"Arch Pathol Lab Med"},{"key":"897_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s40800-016-0031-y","volume":"3","author":"E Paulus","year":"2016","unstructured":"Paulus E, Komperda K, Park G, Fusco J. Anticoagulation therapy considerations in factor VII deficiency. Drug Safety\u2014Case Rep. 2016;3:8.","journal-title":"Drug Safety\u2014Case Rep"},{"key":"897_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/MBC.0000000000000030","volume":"25","author":"LM Baumann Kreuziger","year":"2014","unstructured":"Baumann Kreuziger LM, Datta YH, Johnson AD, Zantek ND, Shanley R, Reding MT. Monitoring anticoagulation in patients with an unreliable prothrombin time\/international normalized ratio: factor II versus chromogenic factor X testing. Blood Coagul Fibrinolysis. 2014;25:232\u20136.","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00897-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00897-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00897-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:49:30Z","timestamp":1790578170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00897-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":6,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["897"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00897-y","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved the final version of the manuscript for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.C. has received speaker and\/or advisory board fees paid to her institution from: AstraZeneca, BMS\/Pfizer, Fresenius Kabi, Leo Pharma, and Servier. E.B-C. has received unrestricted grants from Abbott Laboratories and consulting fees from Abbott Laboratories. She is supported by career awards from the Department of Medicine at McMaster University and the Population Health Research Institute. J.W.E. has received fees \/ honoraria \/ research support from Anthos, AZ, Bayer, BI, BMS, Fresenius Kabi, GSK, Idorsia, Janssen, JnJ, Novartis, Sanofi, Servier, Takeda and Pfizer.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"88"}}